Wall Street analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will report earnings per share (EPS) of ($0.44) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Alpine Immune Sciences’ earnings. Alpine Immune Sciences reported earnings per share of ($2.00) in the same quarter last year, which suggests a positive year-over-year growth rate of 78%. The company is scheduled to announce its next earnings results on Monday, February 12th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($1.16) per share for the current financial year. For the next financial year, analysts expect that the business will report earnings of ($2.25) per share, with EPS estimates ranging from ($3.02) to ($1.48). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Monday, November 13th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.43. The business had revenue of $0.13 million during the quarter.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its holdings in shares of Alpine Immune Sciences by 29.7% during the 4th quarter. Victory Capital Management Inc. now owns 51,551 shares of the biotechnology company’s stock valued at $577,000 after acquiring an additional 11,799 shares in the last quarter. Sowell Financial Services LLC acquired a new stake in shares of Alpine Immune Sciences during the 3rd quarter valued at $162,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Alpine Immune Sciences during the 4th quarter valued at $118,000. 56.63% of the stock is currently owned by institutional investors.
Shares of Alpine Immune Sciences (ALPN) opened at $9.96 on Tuesday. The firm has a market capitalization of $142.71, a price-to-earnings ratio of -1.05 and a beta of 0.17. Alpine Immune Sciences has a twelve month low of $7.20 and a twelve month high of $14.52. The company has a quick ratio of 32.38, a current ratio of 32.38 and a debt-to-equity ratio of 0.05.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Alpine Immune Sciences, Inc. (ALPN) Will Announce Earnings of -$0.44 Per Share” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/13/zacks-brokerages-anticipate-alpine-immune-sciences-inc-alpn-will-announce-earnings-of-0-44-per-share.html.
Alpine Immune Sciences Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.